➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Mallinckrodt
Colorcon
Harvard Business School
McKinsey

Last Updated: July 13, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for keyhole limpet hemocyanin


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug keyhole limpet hemocyanin?

keyhole limpet hemocyanin is an investigational drug.

There have been 29 clinical trials for keyhole limpet hemocyanin. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2011.

The most common disease conditions in clinical trials are Glioblastoma, Lymphoma, and Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), National Institute of Allergy and Infectious Diseases (NIAID), and John Sampson.

There are three hundred and seventy US patents protecting this investigational drug and three international patents.

Recent Clinical Trials for keyhole limpet hemocyanin
TitleSponsorPhase
A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent GlioblastomaMount Sinai Hospital, New YorkPhase 2
A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent GlioblastomaNew York University School of MedicinePhase 2
Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/AdjuvantPCI Biotech ASPhase 1

See all keyhole limpet hemocyanin clinical trials

Clinical Trial Summary for keyhole limpet hemocyanin

Top disease conditions for keyhole limpet hemocyanin
Top clinical trial sponsors for keyhole limpet hemocyanin

See all keyhole limpet hemocyanin clinical trials

US Patents for keyhole limpet hemocyanin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
keyhole limpet hemocyanin   Start Trial Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies Kobenhavns Universitet (Copenhagen, DK) Cancer Research Technology Limited (London, GB)   Start Trial
keyhole limpet hemocyanin   Start Trial Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same   Start Trial
keyhole limpet hemocyanin   Start Trial Modulators of gamma-C-cytokine activity BIONIZ, LLC (Irvine, CA)   Start Trial
keyhole limpet hemocyanin   Start Trial Siderophore-based immunization against gram-negative bacteria Massachusetts Institute of Technology (Cambridge, MA) The Regents of the University of California (Oakland, CA)   Start Trial
keyhole limpet hemocyanin   Start Trial Aquaporin 2 protects cattle from ticks and tick-borne parasites The United States of America, as represented by the Secretary of Agriculture (Washington, DC) Washington State University (Pullman, WA)   Start Trial
keyhole limpet hemocyanin   Start Trial 6-acetylmorphine analogs, and methods for their synthesis and use ALERE SAN DIEGO, INC. (San Diego, CA)   Start Trial
keyhole limpet hemocyanin   Start Trial Phosphohistidine and phosphotyrosine analogues UNIVERSITY OF SHEFFIELD (Sheffield, GB)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for keyhole limpet hemocyanin

Drugname Country Document Number Estimated Expiration Related US Patent
keyhole limpet hemocyanin Australia 2007304590 2026-10-04   Start Trial
keyhole limpet hemocyanin Canada 2665356 2026-10-04   Start Trial
keyhole limpet hemocyanin Canada 2977261 2026-10-04   Start Trial
keyhole limpet hemocyanin European Patent Office 2083868 2026-10-04   Start Trial
keyhole limpet hemocyanin Japan 2010505775 2026-10-04   Start Trial
keyhole limpet hemocyanin World Intellectual Property Organization (WIPO) 2008040362 2026-10-04   Start Trial
keyhole limpet hemocyanin Australia 2015209140 2034-01-24   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Harvard Business School
AstraZeneca
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.